|
KAT2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.04039999965822E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.69920000001345E-06 |
| Normal-vs-Stage2 |
4.426500E-02 |
| Normal-vs-Stage3 |
1.73819999504943E-08 |
| Normal-vs-Stage4 |
5.098200E-03 |
| Stage1-vs-Stage2 |
2.166200E-01 |
| Stage1-vs-Stage3 |
3.263500E-02 |
| Stage1-vs-Stage4 |
8.555600E-01 |
| Stage2-vs-Stage3 |
1.768340E-02 |
| Stage2-vs-Stage4 |
3.353200E-01 |
| Stage3-vs-Stage4 |
3.581200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.65349999750697E-08 |
| Normal-vs-AfricanAmerican |
7.692000E-01 |
| Normal-vs-Asian |
4.367600E-02 |
| Caucasian-vs-AfricanAmerican |
2.320800E-03 |
| Caucasian-vs-Asian |
1.245950E-01 |
| AfricanAmerican-vs-Asian |
2.606800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.998840E-04 |
| Normal-vs-Female |
4.21399999994687E-06 |
| Male-vs-Female |
6.346200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.39609999999058E-05 |
| Normal-vs-Age(41-60Yrs) |
1.61799999998102E-06 |
| Normal-vs-Age(61-80Yrs) |
2.590200E-04 |
| Normal-vs-Age(81-100Yrs) |
9.243200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.598800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.984000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.857400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.359400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.010200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.768000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.08009999999492E-06 |
| Classical-VS-Follicular |
4.015300E-03 |
| Classical-VS-Other |
8.694200E-01 |
| Classical-VS-Normal |
7.96649999967869E-07 |
| Tall-VS-Follicular |
9.47479994461986E-09 |
| Tall-VS-Other |
2.186000E-02 |
| Tall-VS-Normal |
4.35984581770299E-13 |
| Follicular-VS-Other |
5.537900E-02 |
| Follicular-VS-Normal |
1.599380E-01 |
| Other-VS-Normal |
2.076500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.36619999999244E-05 |
| Normal-vs-N1 |
1.241810E-04 |
| N0-vs-N1 |
3.527400E-01 |
|
|
